New combo therapy targets tough pancreatic cancer in early trial

This early-phase trial tested a combination of two drugs—binimetinib and hydroxychloroquine—in 34 people with advanced pancreatic cancer that has a specific gene change (KRAS mutation) and has spread to other parts of the body. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the pair could slow tumor growth. Researchers also tracked side effects and how long patients lived. The study was completed but results are not yet widely reported.